Research programme: CCR2 antagonists - Incyte/Pfizer

Drug Profile

Research programme: CCR2 antagonists - Incyte/Pfizer

Alternative Names: INCB-3344

Latest Information Update: 14 Mar 2012

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Pfizer
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatic fibrosis; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 14 Mar 2012 Discontinued - Preclinical for Hepatic fibrosis in USA (unspecified route)
  • 14 Mar 2012 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 14 Mar 2012 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top